GI
UTHR icon

Gradient Investments’s United Therapeutics UTHR Stock Holding History

Gradient Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$880 – 1811
2023
Q4 		$880 Hold
4
– – ﹤0.01% 1462
2023
Q3 		$903 Hold
4
– – ﹤0.01% 1408
2023
Q2 		$883 Buy
+4
New +$886 ﹤0.01% 1398

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Gradient Investments's UTHR Position: Q1 2024 in Review

Gradient Investments sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 4 shares — an estimated $880 sold.

Gradient Investments first reported a position in UTHR in Q2 2023 and held it in 3 quarters. The position peaked at $903 in Q3 2023. 526 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

  • Gradient Investments reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Gradient Investments sold 4 United Therapeutics shares in Q1 2024, an estimated $880.
  • Gradient Investments first reported a position in United Therapeutics in Q2 2023 and held it in 3 quarters.
  • Gradient Investments's United Therapeutics position peaked at $903 in Q3 2023.
  • 526 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.